Success Story: Swift Dual NIW & EB1A Approval for Internal Medicine Resident with Premium Processing and Our Expert Guidance
Client’s Testimonial:
“Working with Chen immigration was seamless, their methods are tried and true, and I knew I could count on them to get the job done.”
On December 17th, 2024, and August 8th, 2025, we received another I-140 NIW (National Interest Waiver) and EB1A (Alien of Extraordinary Ability) Approvals for an Internal Medicine Resident in the Field of Human Molecular Genetics (Approval Notice).
General Field: Human Molecular Genetics
Position at the Time of Case Filing: Internal Medicine Resident
Country of Origin: Israel
State of Residence at the Time of Filing: Ohio
Approval Notice Date: December 17th, 2024 (NIW) & August 8th, 2025 (EB1A)
Processing Time: 1 month, 26 days (NIW), and 15 days (EB1A) (Premium Processing Requested)
Case Summary:
We are pleased to share the approval of both an EB-2 NIW (National Interest Waiver) petition and an EB1A (Alien of Extraordinary Ability) petition for a distinguished researcher with an M.D. and a Ph.D. in human molecular genetics and biochemistry. This client has built an impressive record of contributions at the intersection of human molecular genetics, genetic engineering models, and tailored drug design. At the time of filing, the client was engaged in clinical and research activities in the United States, demonstrating both practical and scientific leadership in advancing genetic research and medical innovation.
Research Focus and Contributions:
The client’s work centers on advancing our understanding of complex genetic disorders, particularly through the development of innovative genetic engineering models and drug design methodologies. Of particular note is the client’s pioneering research on somatic mutations in the brains of individuals with Alzheimer’s disease. By investigating these mutations, the client has shed light on how genetic mechanisms drive neurodegenerative processes, creating new pathways for both diagnosis and therapeutic intervention. This work has had substantial implications for the treatment of conditions like Alzheimer’s disease and syndromic autism, providing critical tools to support the broader medical and scientific communities.
Publications and Citations:
The client has authored 12 peer-reviewed journal articles, including first- and co-first-authored works, in highly regarded international journals. These publications have been cited 465 times, reflecting strong recognition and reliance on the client’s findings across the global scientific community. Importantly, several of these papers are among the top-cited in the field of molecular biology and genetics for their respective years, underscoring the significant influence and sustained impact of the client’s work.
Peer Review and Scholarly Engagement:
The client has completed at least 33 reviews for highly selective journals, including venues ranked among the top in cell biology and molecular sciences. This extensive peer review activity highlights the client’s authority and respected judgment in the field, as editors consistently rely on their expertise to uphold the quality and rigor of published scientific research.
Recognition and Support:
The client’s research achievements have been further validated through funding from prestigious organizations such as the U.S.–Israel Binational Science Foundation and the National Science Foundation, underscoring the trust placed in the significance and potential impact of this work. Additionally, the petition was strengthened by two letters of recommendation from internationally recognized experts in human molecular genetics, who attested to the originality, significance, and lasting influence of the client’s contributions.
“He has demonstrated his expertise through his impactful research on genetic mutations and their relationship to developmental deficits. Combined with his extensive and impressive list of peer-reviewed publications, it is clear that [Client] is an irreplaceable presence in the research sphere.”
Well Positioned to Advance the Proposed Endeavor:
With an M.D., advanced research training, and ongoing engagement in both clinical and research pathways, the client is uniquely positioned to continue advancing genetic engineering and tailored drug design in the United States. Their work bridges laboratory research with translational applications, enabling new therapeutic strategies that directly support national healthcare priorities, including addressing the burdens of neurodegenerative diseases and genetic disorders.
Approval and Outcome:
The EB1A petition was approved in August 2025, following the earlier NIW approval in December 2024, reflecting USCIS’s recognition of the client’s extraordinary achievements and potential to contribute significantly to the U.S. scientific and medical landscape. NAILG is proud to have successfully represented this client, whose continued research promises to yield innovations with lasting benefits for patients, clinicians, and researchers worldwide.